Overview
Mark Mihanovic said that, despite the recent biotech IPO boom, he did not “think we’ve seen the same dynamic as we saw in 1999,” the last IPO bubble in the industry. Mr. Mihanovic continued, “Investors are looking for market potential and management with a track record,” while the companies themselves are “viewing an IPO as just another financing event. Five years ago, there just was not an appetite for companies at an earlier stage.” Read the full article
